Citius Pharmaceuticals, Inc.
CTXR Healthcare Biotechnology
In the quarter to June 2026, EPS grew 57.5% and free cash flow fell 60.5%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow CTXR
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Cash and Short Term Investments |
17.01 | 4.59 | 7.72 | 4.25 |
+8 more quarters Free account |
Receivables |
0.69 | 1.08 | 4.05 | — | |
Inventory |
22.63 | 22.66 | 22.64 | 22.29 | |
Total current assets |
43.33 | 31.69 | 37.95 | 27.93 | |
Long-Term Investments |
0.04 | 0.04 | 0.04 | 0.04 | |
Goodwill and Intangible Assets (Total) |
9.35 | 9.35 | 9.35 | 9.35 | |
Long-term assets (Other) |
88.79 | 90.51 | 92.23 | 92.80 | |
Total non-current assets |
98.92 | 100.85 | 102.45 | 103.00 | |
Total Assets |
142.26 | 132.54 | 140.39 | 130.94 | |
Notes Payable |
— | — | 1.00 | 1.00 | |
Accounts Payable |
8.04 | 9.45 | 11.02 | 13.69 | |
Accrued Expenses |
27.79 | 27.74 | 7.79 | 7.48 | |
Other current liabilities |
15.65 | 17.65 | 18.25 | 22.65 | |
Total current liabilities |
51.65 | 55.02 | 38.21 | 44.91 | |
Long Term Debt (Total) |
6.41 | — | — | — | |
Long Term Tax Liability (Deferred) |
7.70 | 7.80 | 8.04 | 7.77 | |
Total non-current liabilities |
14.70 | 8.44 | 8.72 | 8.50 | |
Total liabilities |
66.35 | 63.46 | 46.92 | 53.41 | |
Additional Paid In Capital |
343.70 | 329.78 | 326.96 | 306.34 | |
Common Stock (Net) |
0.03 | 0.02 | 0.02 | 0.02 | |
Retained Earnings |
(277.12) | (268.26) | (247.02) | (238.80) | |
Common Equity (Total) |
75.91 | 69.08 | 93.47 | 77.53 | |
Shareholders Equity (Total) |
75.91 | 69.08 | 93.47 | 77.53 | |
Shareholders Equity and Liabilities (Total) |
142.26 | 132.54 | 140.39 | 130.94 | |
Shares (Common) |
27.45 | 22.38 | 22.38 | 18.07 | |
Shareholders Equity (Tangible) |
66.56 | 59.74 | 84.12 | 68.18 | |
Net Debt |
(10.60) | (4.59) | (7.72) | (4.25) | |
Total Debt |
6.41 | — | — | — |